Frequently Asked Questions
The market is segmented based on Global Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA), Alpha-Linolenic Acid (ALA)), Forms (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer, Others), Population Type (Adults and Children), Distribution Channel (Direct, Indirect) – Industry Trends and Forecast to 2030.
.
The Global Omega 3 Ingredients For Pharmaceuticals Market size was valued at USD 733.50 USD Million in 2022.
The Global Omega 3 Ingredients For Pharmaceuticals Market is projected to grow at a CAGR of 11.5% during the forecast period of 2023 to 2030.
The major players operating in the market include Avestia Pharma, Novasep, AbbVie , KD Pharma Group, BASF SE, Corbion, DSM, AstraZeneca, GSK plc., Fresenius Kabi AG, Croda International Plc, AMARIN CORPORATION, ANI Pharmaceuticals , Epax, Strides Pharma Science Limited, Pharma Marine AS, KinOmega Biopharm , Camber Pharmaceuticals .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
